Central Nervous System Drugs

Central Nervous System Drugs Market Outlook

The global Central Nervous System (CNS) drugs market is poised to reach a valuation of approximately USD 100 billion by the year 2033, exhibiting a compound annual growth rate (CAGR) of around 7% from 2025 to 2033. This substantial growth is driven by a combination of factors, including the rising prevalence of mental health disorders, increasing awareness about mental health issues, and advancements in drug development technologies. Additionally, the global push towards destigmatizing mental health has led to greater acceptance of seeking treatment, thereby expanding the market. Furthermore, ongoing research and innovation in the field of neuroscience are paving the way for new drug approvals, which are expected to significantly contribute to market growth. With an expanding therapeutic landscape and a growing understanding of CNS-related conditions, the market is anticipated to witness robust growth in the coming years.

Growth Factor of the Market

Several crucial factors are driving the growth of the Central Nervous System drugs market. Firstly, the rising incidence of mental health conditions, such as depression, anxiety, and schizophrenia, has led to an increasing demand for effective therapeutic options. Reports suggest that more than 260 million people globally suffer from depression, highlighting the urgent need for comprehensive treatment solutions. Secondly, the aging population is particularly vulnerable to CNS disorders, which has resulted in a higher demand for CNS medications. Additionally, advancements in pharmacotherapy and the introduction of novel CNS drugs have expanded treatment options, significantly impacting patient outcomes. Thirdly, the growing acceptance of mental health treatment reduces stigma and encourages individuals to seek help. Moreover, increased funding and support for mental health initiatives globally further enhance market growth. Lastly, the development of personalized medicine in CNS treatment is expected to revolutionize therapy approaches, driving market progression.

Key Highlights of the Market

• The CNS drugs market is anticipated to achieve a valuation of USD 100 billion by 2033.
• The market is growing at a CAGR of around 7% during the forecast period from 2025 to 2033.
• Rising prevalence of mental disorders and increased awareness are significant growth drivers.
• Advancements in drug development technologies are enhancing treatment options.
• Research into personalized medicine is expected to shape future therapeutic landscapes.

By Drug Class

Antidepressants:

Antidepressants represent a significant segment of the CNS drugs market, primarily used in the treatment of major depressive disorders and other mood-related conditions. These medications work by altering the balance of neurotransmitters in the brain, such as serotonin and norepinephrine, which are crucial for regulating mood. The most commonly prescribed classes of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants. The rising incidence of depression, particularly in developed regions, has propelled the demand for these drugs, supported by the growing acceptance of mental health treatment. Ongoing research into more effective and faster-acting antidepressants, coupled with the introduction of novel formulations, is expected to further enhance the growth of this segment.

Antipsychotics:

Antipsychotics are another essential category within the CNS drugs market, primarily indicated for the treatment of schizophrenia and bipolar disorder. These medications help manage psychotic symptoms such as hallucinations, delusions, and disorganized thinking. There are two main classes of antipsychotics: first-generation (typical) and second-generation (atypical) antipsychotics. Recent trends show a shift towards atypical antipsychotics due to their favorable side effect profile and efficacy in treating a wider range of symptoms. The increasing prevalence of schizophrenia and other psychotic disorders, combined with a growing focus on improving patient quality of life, is fueling the demand for antipsychotic medications. Continuous research aimed at unlocking novel therapeutic targets and developing drugs with fewer side effects is expected to drive this segment's growth.

Mood Stabilizers:

Mood stabilizers are a vital component of the CNS drugs market, primarily utilized in the treatment of bipolar disorder. These medications help regulate mood swings, preventing both manic and depressive episodes. Commonly used mood stabilizers include lithium, valproate, and lamotrigine. The growing recognition of bipolar disorder as a serious mental health condition is fostering increased diagnosis and treatment, leading to heightened demand for mood stabilizers. The market for mood stabilizers is further driven by advancements in pharmacological research, resulting in the development of new compounds with enhanced efficacy and safety profiles. Moreover, educational initiatives aimed at increasing awareness about bipolar disorder are also contributing to market growth.

Anxiolytics:

Anxiolytics are a critical drug class within the CNS market, primarily prescribed for the management of anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder. Benzodiazepines are the most widely used anxiolytics, known for their fast-acting effects in alleviating anxiety symptoms. However, the potential for dependence and withdrawal issues has led to increased scrutiny and a push for alternative therapies, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT). The rising prevalence of anxiety disorders, exacerbated by modern-day stressors, is driving the demand for anxiolytics. Continuous research into the development of non-benzodiazepine anxiolytics is also expected to shape the market landscape positively.

Stimulants:

Stimulants are primarily used to treat attention-deficit hyperactivity disorder (ADHD) and are a crucial segment of the CNS drugs market. Medications such as methylphenidate and amphetamines work by increasing dopamine and norepinephrine levels in the brain, improving focus and attention in individuals with ADHD. The incidence of ADHD is on the rise, particularly among children and adolescents, leading to a significant demand for stimulant medications. Furthermore, growing awareness about ADHD and its implications on academic performance and daily functioning is propelling market growth. Continued research and development efforts aim to enhance the efficacy and safety of stimulant medications, further solidifying their role in the CNS drugs market.

By Indication

Depression:

Depression is one of the most prevalent mental health disorders globally, making it a substantial segment within the CNS drugs market. The increasing awareness and recognition of depression as a serious health issue have led to a surge in treatment-seeking behavior among affected individuals. This has driven the demand for various antidepressant medications, which are specifically tailored to manage depressive symptoms. Moreover, the rise in the geriatric population, who are more susceptible to depression, further propels market growth. Ongoing advancements in research are also resulting in the development of new and innovative treatments, including rapid-acting antidepressants that promise better outcomes for patients.

Schizophrenia:

Schizophrenia is a chronic and severe mental disorder that significantly impacts individuals' perceptions and behavior. The growing prevalence of schizophrenia globally has resulted in a heightened demand for antipsychotic medications, which form a key segment of the CNS drugs market. Effective management of schizophrenia involves the use of various antipsychotics, as these medications help alleviate symptoms such as hallucinations and delusions. As mental health awareness increases, more individuals are being diagnosed and treated, further driving market growth. Additionally, ongoing research into personalized treatment approaches and novel therapeutic agents is expected to enhance the management of schizophrenia, contributing to the market's progress.

Bipolar Disorder:

Bipolar disorder is characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). Treatment for bipolar disorder often involves a combination of mood stabilizers and antipsychotics. The increasing recognition of bipolar disorder as a significant mental health concern is driving the demand for effective treatment options. With rising awareness and a greater focus on mental health, more individuals are seeking help and receiving timely diagnosis and treatment. Furthermore, advancements in pharmacotherapy and ongoing research into new medications aimed at improving patient outcomes are expected to propel the growth of the bipolar disorder indication segment within the CNS drugs market.

Anxiety Disorders:

Anxiety disorders encompass a range of conditions, such as generalized anxiety disorder, panic disorder, and social anxiety disorder. The growing prevalence of anxiety disorders in modern society is significantly influencing the CNS drugs market, with a rising demand for anxiolytic medications. The ongoing dialogue about mental health and the reduction of stigma associated with seeking treatment have led to increased patient engagement. Additionally, as more individuals are diagnosed with anxiety disorders, there is a growing need for effective pharmacological interventions. The market is also being shaped by the development of innovative treatments that offer better efficacy and fewer side effects, further enhancing patient outcomes.

ADHD:

Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder primarily affecting children but can also persist into adulthood. The increasing diagnosis rates of ADHD have led to a significant rise in the demand for stimulant medications, which are the first-line treatment for managing this condition. The growing awareness among parents and educators about ADHD and its impact on academic performance and daily functioning has further contributed to the market's growth. Additionally, advancements in pharmaceutical research are leading to the development of newer and more effective ADHD medications, which are expected to positively influence market dynamics. The combination of rising prevalence and improved treatment options positions the ADHD indication segment as a key driver of growth within the CNS drugs market.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of CNS drugs, particularly for patients with severe mental health conditions who require immediate and specialized care. These pharmacies offer a range of CNS medications and are often involved in the direct management of patients' drug therapy regimens, ensuring optimal medication adherence and monitoring for adverse effects. The increasing admission rates for psychiatric illnesses in hospitals, combined with the need for specialized care, is driving the demand for CNS drugs through hospital pharmacies. Moreover, collaborations between hospitals and pharmaceutical companies for drug supply and distribution are expected to enhance market accessibility and growth.

Retail Pharmacies:

Retail pharmacies are another significant distribution channel for CNS drugs, catering to outpatient needs for various mental health conditions. The convenience offered by retail pharmacies allows patients to access their medications easily, contributing to better treatment adherence. The increasing prevalence of mental health issues, along with growing awareness and acceptance of mental health treatment, is driving the demand for CNS medications through retail channels. Additionally, the strategic expansion of retail pharmacy chains and the introduction of online prescription services are expected to further enhance market reach and patient access to CNS drugs.

Online Pharmacies:

Online pharmacies are emerging as a vital distribution channel for CNS drugs, providing patients with the convenience of ordering medications from the comfort of their homes. This trend has gained traction in recent years, driven by the growing acceptance of telemedicine and digital healthcare solutions. The COVID-19 pandemic has accelerated the shift towards online pharmacy services, as many patients sought safe and accessible options for medication procurement. The ability of online pharmacies to offer competitive pricing and a wide range of CNS medications is also attracting more consumers. As technology continues to evolve, the online pharmacy sector is expected to play an increasingly important role in the distribution of CNS drugs.

By Route of Administration

Oral:

Oral administration is the most common route for delivering CNS drugs, as it is convenient and generally well-accepted by patients. Many antidepressants, antipsychotics, and anxiolytics are available in oral formulations, allowing for ease of use and effective management of symptoms. The preference for oral medications is driven by their accessibility and the ability to adhere to treatment regimens easily. Furthermore, ongoing research is focused on enhancing the bioavailability and efficacy of orally administered CNS drugs, which is expected to support market growth. Continuous innovation in drug formulations is aimed at improving patient compliance, particularly among those with chronic mental health conditions.

Injectable:

Injectable medications are an important segment in the administration of CNS drugs, particularly for patients who may struggle with adherence to oral medications. This route is often employed in acute settings or for patients with severe psychiatric disorders requiring immediate intervention. Long-acting injectable formulations are increasingly being developed for antipsychotics and mood stabilizers, allowing for less frequent dosing and improved patient compliance. The growing recognition of the need for innovative delivery methods to enhance treatment adherence is driving the market for injectable CNS drugs. Furthermore, the development of novel delivery systems, such as pre-filled syringes and auto-injectors, is expected to bolster this segment's growth.

Transdermal:

Transdermal drug delivery systems are gaining traction in the CNS drugs market due to their ability to provide a steady release of medication through the skin, enhancing convenience and minimizing side effects associated with oral administration. Transdermal patches are particularly beneficial for patients who may have difficulty swallowing pills or those who prefer not to take medications orally. This route of administration is being explored for various CNS medications, including those used for mood disorders and ADHD. The growing focus on patient-centric treatment options and advancements in transdermal technology are expected to drive the demand for transdermal CNS drugs in the coming years.

By Region

The regional analysis of the Central Nervous System drugs market reveals North America as the largest market, accounting for approximately 40% of the global market share. This dominance is primarily attributed to the high prevalence of mental health disorders, increased healthcare spending, and a well-established pharmaceutical sector. The region is expected to continue its growth trajectory, with a CAGR of around 6.5% during the forecast period, driven by ongoing research and development efforts, as well as a growing acceptance of mental health treatment among the population. Furthermore, the presence of major pharmaceutical companies and advanced healthcare infrastructure are bolstering the market in North America.

Europe is the second-largest regional market for CNS drugs, holding nearly 30% of the global market share. The increasing focus on mental health awareness and the implementation of supportive policies for mental health treatment are driving growth in this region. Additionally, the rising incidence of mental disorders, coupled with advancements in drug development, is also contributing to market expansion in Europe. The Asia Pacific region is expected to exhibit the highest growth rate, with a projected CAGR of over 8% during the forecast period, fueled by increasing population awareness, growing disposable incomes, and a rising prevalence of mental health disorders. Latin America and the Middle East & Africa are also expected to experience steady growth, supported by improving healthcare infrastructure and increasing access to mental health medications.

Opportunities

The Central Nervous System drugs market is witnessing various opportunities that are expected to propel its growth in the coming years. One of the foremost opportunities lies in the increasing investment in mental health research and development. Governments and private entities are showing a growing commitment towards funding innovative approaches to treat and manage mental health disorders. This financial backing is likely to accelerate the discovery of new drug compounds and therapeutic targets, ultimately expanding the range of treatment options available to patients. Furthermore, the integration of technology into mental health treatment, such as digital therapeutics and telemedicine, presents a unique opportunity to reach previously underserved populations, enhancing access to effective CNS drugs.

Additionally, the rising prevalence of mental health disorders, particularly among the aging population, presents a significant opportunity for market players to develop specialized treatments tailored to this demographic. As the societal and economic burden of untreated mental illnesses continues to grow, the demand for effective therapeutic interventions will increase, providing companies with opportunities to innovate and capture market share. The growing trend towards personalized medicine in mental health treatment is another key opportunity, as it allows for more targeted and effective therapies that can cater to individual patient needs and preferences. By capitalizing on these opportunities, companies can position themselves favorably within the expanding CNS drugs market.

Threats

Despite the promising growth trajectory of the Central Nervous System drugs market, several threats could potentially hinder its progress. One of the major threats is the increasing regulatory scrutiny surrounding the approval and marketing of CNS medications. Regulatory bodies are becoming more vigilant regarding the safety and efficacy of drugs, which can lead to extended approval timelines and increased costs for pharmaceutical companies. Additionally, the rising prevalence of generic drugs and biosimilars may also pose a threat to market players, as these alternatives often offer similar therapeutic benefits at a lower cost, thereby impacting the revenue of branded CNS medications. Furthermore, the stigma associated with mental health treatment may deter some individuals from seeking help, thereby limiting the overall market potential.

Another significant threat facing the CNS drugs market is the growing concern regarding the potential for abuse and dependency associated with certain classes of medications, particularly stimulants and benzodiazepines. This concern has led to stricter regulations and prescribing guidelines, which may restrict access to these essential medications for patients in need. Moreover, the evolving landscape of mental health treatment, including the rise of alternative therapies and holistic approaches, could disrupt traditional pharmaceutical models, posing challenges for established market players. Addressing these threats will require proactive strategies and adaptability from companies operating within the CNS drug sector.

Competitor Outlook

• Pfizer Inc.
• Johnson & Johnson
• GlaxoSmithKline plc
• AbbVie Inc.
• Merck & Co., Inc.
• Roche Holding AG
• Esai Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• AstraZeneca plc
• Novartis AG
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.
• Gilead Sciences, Inc.

The competitive landscape of the Central Nervous System drugs market is characterized by the presence of several key players who are actively engaged in developing innovative therapeutic solutions. These companies are focused on enhancing their product portfolios through robust research and development efforts, collaborations, and acquisitions. Notably, major pharmaceutical companies such as Pfizer Inc., Johnson & Johnson, and AbbVie Inc. dominate the market, leveraging their extensive resources to innovate and introduce new CNS drugs. These companies are investing heavily in clinical trials to validate the safety and efficacy of their products, which is vital for gaining approval from regulatory agencies and establishing a solid market presence.

Moreover, the market is also witnessing an influx of biotechnology firms and startups that are bringing novel approaches to CNS drug development. These companies are often focused on targeting specific mechanisms of action, thereby revolutionizing treatment paradigms in mental health care. With advancements in personalized medicine and genetic research, these emerging players are expected to play a significant role in shaping the future of the CNS drugs market. The competitive dynamics are further influenced by the growing focus on digital health solutions, with companies exploring technology-driven approaches to enhance patient engagement and adherence to treatment.

Among the major players, Roche Holding AG and GlaxoSmithKline plc are recognized for their diverse portfolios in CNS therapeutics, covering a range of indications from depression to schizophrenia. Their commitment to ongoing research and collaboration with academic institutions positions them favorably to leverage emerging trends in mental health treatment. Additionally, Lundbeck A/S is a notable player specializing in psychiatric and neurological disorders, with a strong emphasis on innovative drug development. The company's pipelines are focused on addressing unmet medical needs in mental health care, ensuring that it remains a key competitor in the CNS drugs market. Overall, the competitive landscape is dynamic and evolving, with traditional pharmaceutical companies and emerging innovators competing to provide effective solutions for CNS disorders.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Lundbeck A/S
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Esai Co., Ltd.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca plc
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Gilead Sciences, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boehringer Ingelheim GmbH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Otsuka Pharmaceutical Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Central Nervous System Drugs Market, By Drug Class
    • 6.1.1 Antidepressants
    • 6.1.2 Antipsychotics
    • 6.1.3 Mood Stabilizers
    • 6.1.4 Anxiolytics
    • 6.1.5 Stimulants
  • 6.2 Central Nervous System Drugs Market, By Indication
    • 6.2.1 Depression
    • 6.2.2 Schizophrenia
    • 6.2.3 Bipolar Disorder
    • 6.2.4 Anxiety Disorders
    • 6.2.5 ADHD
  • 6.3 Central Nervous System Drugs Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Central Nervous System Drugs Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Injectable
    • 6.4.3 Transdermal

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Central Nervous System Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Central Nervous System Drugs market is categorized based on

By Drug Class

• Antidepressants
• Antipsychotics
• Mood Stabilizers
• Anxiolytics
• Stimulants

By Indication

• Depression
• Schizophrenia
• Bipolar Disorder
• Anxiety Disorders
• ADHD

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Route of Administration

• Oral
• Injectable
• Transdermal

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Johnson & Johnson
• GlaxoSmithKline plc
• AbbVie Inc.
• Merck & Co., Inc.
• Roche Holding AG
• Esai Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• AstraZeneca plc
• Novartis AG
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.
• Gilead Sciences, Inc.